ICAD ICADE


$ 3.88 $ 0.14 (3.75 %)    

Wednesday, 16-Jul-2025 15:59:50 EDT
QQQ $ 597.40 $ 0.00 (0 %)
DIA $ 459.00 $ 0.00 (0 %)
SPY $ 659.05 $ 0.00 (0 %)
TLT $ 91.22 $ 0.00 (0 %)
GLD $ 396.72 $ 0.00 (0 %)
$ 3.87
$ 3.74
$ 0.00 x 0
$ 0.00 x 0
-- - --
$ 1.19 - $ 4.02
190,127
na
nm
$ 1.17
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 icad-q1-adj-eps-002-beats-006-estimate-sales-487m-beat-453m-estimate

icad (NASDAQ:ICAD) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.06) by 66.67...

 laidlaw--co-downgrades-icad-to-hold

Laidlaw & Co. analyst Yale Jen downgrades icad (NASDAQ:ICAD) from Buy to Hold.

 us-stock-likely-to-open-lower-as-us-china-tariff-war-continues-valuations-are-now-looking-more-compelling-says-expert

U.S. stock futures declined on Wednesday following a muted day of trading on Tuesday. Futures of indices were lower in premarket.

Core News & Articles

The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the ac...

 icad-q4-2024-adj-eps-003-beats-005-estimate-sales-5408m-beat-4827m-estimate

icad (NASDAQ:ICAD) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.05) by 40 pe...

 icad-expects-q4-2024-revenue-between-51m-53m-total-annual-recurring-revenue-reaches-98m-up-11-yoy-closed-106-deals-including-19-cloud-deals

iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company"), a global leader on a mission to create a world where cancer...

 icad-presents-next-generation-ai-solutions-and-a-second-read-ai-partnership-with-cascaid-health-at-rsna-2024

iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company"), a global leader in clinically proven AI-powered cancer dete...

 icad-q3-2024-adj-eps-007-beats-008-estimate-sales-4217m-miss-4521m-estimate

icad (NASDAQ:ICAD) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION